Corvus Pharmaceuticals Inc
CRVS7.700USD
+0.220+2.94%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
575.05MMarket Cap
LossP/E TTM
More Details of Corvus Pharmaceuticals Inc Company
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Corvus Pharmaceuticals Inc Info
Ticker SymbolCRVS
Company nameCorvus Pharmaceuticals Inc
IPO dateMar 23, 2016
CEOMiller (Richard A)
Number of employees31
Security typeOrdinary Share
Fiscal year-endMar 23
Address863 Mitten Rd Ste 102
CityBURLINGAME
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94010-1311
Phone16509004520
Websitehttps://www.corvuspharma.com/
Ticker SymbolCRVS
IPO dateMar 23, 2016
CEOMiller (Richard A)
Company Executives of Corvus Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Richard A. Miller, M.D.
Dr. Richard A. Miller, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.32M
+31.66%
Mr. Leiv Lea
Mr. Leiv Lea
Chief Financial Officer
Chief Financial Officer
282.44K
--
Dr. Linda S. Grais, M.D., J.D.
Dr. Linda S. Grais, M.D., J.D.
Independent Director
Independent Director
10.00K
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Mr. Jeffrey S. Arcara
Mr. Jeffrey S. Arcara
Senior Vice President, Chief Business Officer
Senior Vice President, Chief Business Officer
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
Mr. Ian T. Clark
Mr. Ian T. Clark
Independent Director
Independent Director
--
--
Dr. William B. Jones, Ph.D.
Dr. William B. Jones, Ph.D.
Senior Vice President - Pharmaceutical Development
Senior Vice President - Pharmaceutical Development
--
--
Mr. Richard van Den Broek
Mr. Richard van Den Broek
Independent Director
Independent Director
--
--
Mr. David Moore
Mr. David Moore
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Richard A. Miller, M.D.
Dr. Richard A. Miller, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.32M
+31.66%
Mr. Leiv Lea
Mr. Leiv Lea
Chief Financial Officer
Chief Financial Officer
282.44K
--
Dr. Linda S. Grais, M.D., J.D.
Dr. Linda S. Grais, M.D., J.D.
Independent Director
Independent Director
10.00K
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Mr. Jeffrey S. Arcara
Mr. Jeffrey S. Arcara
Senior Vice President, Chief Business Officer
Senior Vice President, Chief Business Officer
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
9.59%
Point72 Asset Management, L.P.
8.64%
BlackRock Institutional Trust Company, N.A.
5.37%
The Vanguard Group, Inc.
4.65%
Adams Street Partners, LLC
4.39%
Other
67.36%
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
9.59%
Point72 Asset Management, L.P.
8.64%
BlackRock Institutional Trust Company, N.A.
5.37%
The Vanguard Group, Inc.
4.65%
Adams Street Partners, LLC
4.39%
Other
67.36%
Shareholder Types
Shareholders
Proportion
Private Equity
18.22%
Investment Advisor
15.06%
Hedge Fund
10.65%
Investment Advisor/Hedge Fund
9.06%
Individual Investor
3.95%
Venture Capital
2.99%
Research Firm
0.95%
Pension Fund
0.17%
Bank and Trust
0.10%
Other
38.85%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
198
42.72M
67.87%
+28.18K
2025Q3
198
42.69M
68.03%
+692.60K
2025Q2
185
42.00M
50.82%
+5.57M
2025Q1
150
36.93M
58.80%
-3.14M
2024Q4
137
38.41M
48.94%
+8.38M
2024Q3
107
30.42M
48.36%
+2.42M
2024Q2
103
27.99M
53.72%
-192.26K
2024Q1
112
18.29M
54.96%
-8.66M
2023Q4
115
19.58M
56.23%
-2.90K
2023Q3
125
19.59M
56.04%
-307.97K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
OrbiMed Advisors, LLC
7.17M
9.62%
+221.35K
+3.19%
Jun 30, 2025
Point72 Asset Management, L.P.
7.04M
9.45%
+4.25M
+152.63%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.62M
4.85%
+2.65M
+274.72%
Jun 30, 2025
The Vanguard Group, Inc.
3.28M
4.4%
+786.56K
+31.54%
Jun 30, 2025
Adams Street Partners, LLC
3.28M
4.4%
--
--
Jun 30, 2025
RTW Investments L.P.
2.68M
3.6%
--
--
Jun 30, 2025
Miller (Richard A)
2.32M
3.12%
+559.07K
+31.66%
May 07, 2025
Vivo Capital, LLC
2.23M
3%
--
--
Jun 30, 2025
Foresite Capital Management, LLC
1.73M
2.32%
+150.00K
+9.49%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.36M
1.83%
+771.45K
+130.69%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.28%
Invesco NASDAQ Future Gen 200 ETF
0.75%
Tema Oncology ETF
0.72%
iShares Micro-Cap ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.08%
Invesco Nasdaq Biotechnology ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
iShares Biotechnology ETF
0.04%
iShares Russell 2000 Growth ETF
0.03%
Proshares Ultra Russell 2000
0.02%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.28%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.75%
Tema Oncology ETF
Proportion0.72%
iShares Micro-Cap ETF
Proportion0.09%
ProShares Ultra Nasdaq Biotechnology
Proportion0.08%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.05%
iShares Biotechnology ETF
Proportion0.04%
iShares Russell 2000 Growth ETF
Proportion0.03%
Proshares Ultra Russell 2000
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Corvus Pharmaceuticals Inc?
The top five shareholders of Corvus Pharmaceuticals Inc are:
OrbiMed Advisors, LLC holds 7.17M shares, accounting for 9.62% of the total shares.
Point72 Asset Management, L.P. holds 7.04M shares, accounting for 9.45% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.62M shares, accounting for 4.85% of the total shares.
The Vanguard Group, Inc. holds 3.28M shares, accounting for 4.40% of the total shares.
Adams Street Partners, LLC holds 3.28M shares, accounting for 4.40% of the total shares.
OrbiMed Advisors, LLC holds 7.17M shares, accounting for 9.62% of the total shares.
Point72 Asset Management, L.P. holds 7.04M shares, accounting for 9.45% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.62M shares, accounting for 4.85% of the total shares.
The Vanguard Group, Inc. holds 3.28M shares, accounting for 4.40% of the total shares.
Adams Street Partners, LLC holds 3.28M shares, accounting for 4.40% of the total shares.
What are the top three shareholder types of Corvus Pharmaceuticals Inc?
The top three shareholder types of Corvus Pharmaceuticals Inc are:
OrbiMed Advisors, LLC
Point72 Asset Management, L.P.
BlackRock Institutional Trust Company, N.A.
OrbiMed Advisors, LLC
Point72 Asset Management, L.P.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Corvus Pharmaceuticals Inc (CRVS)?
As of 2025Q4, 198 institutions hold shares of Corvus Pharmaceuticals Inc, with a combined market value of approximately 42.72M, accounting for 67.87% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.16%.
What is the biggest source of revenue for Corvus Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Corvus Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
